BioInvent Has Received Milestones from Bayer and Servier

Regulatory News:

BioInvent (STO:BINV)

BioInvent International (OMXS: BINV) today announced that it has received two separate milestone payments, together worth 1 MEuro, as a result of milestones being reached under collaborations with Bayer Pharma AG (Bayer) and Servier.

The milestone payment from Bayer was paid as the first patient was enrolled in a phase I clinical trial of an antibody identified from BioInvent’s n-CoDeR® library.

The milestone payment from Servier was due as antibodies identified from the n-CoDeR® library against an undisclosed target structure provided by Servier have reached in vivo proof of concept. According to the agreement signed by the parties in 2012, Servier has access to BioInvent’s preclinical expertise in optimizing antibody candidates for further clinical development.

Specific milestone payments were not disclosed.

-- END –

To the editors:

About Servier

Founded in 1954, Servier is an independent French pharmaceutical research company. Its development is based on the continuous pursuit of innovation in the therapeutic areas of cardiovascular -, metabolic-, neurologic-, psychiatric-, bone- and joint diseases as well as cancer.

In 2013, the company recorded a turnover of 4.2 billion euros. 91% of Servier drugs are consumed outside of France. 27% of turnover from Servier drugs were reinvested in Research and Development in 2013. With a strong international presence in 140 countries, Servier employs more than 21 000 people worldwide. The Servier Group contributed 35% to the 2013 French trade surplus in the pharmaceuticals sector.

About BioInvent

BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer.

The company has unique expertise in antibody drug development from initial concept to late clinical phase. The screening tool F.I.R.S.TTM and the antibody library n-CoDeR® are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of new drugs, and provide BioInvent with the right to milestone payments and royalties on sales. These partners include Bayer Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Servier, and Xoma. More information is available at www.bioinvent.com.

BioInvent International AB (publ)

Co. reg. No. 556537-7263

Visiting address: Sölvegatan 41

Mailing address: 223 70 LUND

Phone: +46 (0)46 286 85 50

info@bioinvent.com

www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Information disclosed in this press release is provided herein pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.40 a.m. CET, on 7 July, 2014.

This information was brought to you by Cision http://news.cision.com